Novo Nordisk A/S (NOVO-B)의 가격은 얼마입니까?

Novo Nordisk A/S (NOVO-B)의 가격은 $47.14입니다.

Novo Nordisk A/S (NOVO-B)의 시가 총액은 무엇입니까?

Novo Nordisk A/S (NOVO-B)의 시가 총액은 $209.42B입니다.

Novo Nordisk A/S (NOVO-B) PSR

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

연도	P/S 비율	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

P/S 비율

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	P/S 비율	P/S 비율 차이	국가
Eli Lilly and Company LLY.US	14.97	235.27%	US
Johnson & Johnson JNJ.US	6.31	41.28%	US
AbbVie Inc. ABBV.US	7.06	58.02%	US
Roche Holding AG RO.SW	4.66	4.33%	CH
Merck & Co., Inc. MRK.US	4.90	9.81%	US

회사

P/S 비율

P/S 비율 차이

국가

Eli Lilly and Company

LLY.US

14.97

235.27%

Johnson & Johnson

JNJ.US

6.31

41.28%

AbbVie Inc.

ABBV.US

7.06

58.02%

Roche Holding AG

RO.SW

4.66

4.33%

Merck & Co., Inc.

MRK.US

4.90

9.81%

Novo Nordisk A/S

NOVO-B

카테고리